News and Announcements
TAIM Investments monthly performance update: October 2018
- Published October 04, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
TAIM’s success has been a long time coming. After 14 years in business, 8 of these were spent on development and 6 years on methodology, TAIM have established operation in a regulated environment.
TAIM Investments operates two Australian equities investment funds and they are proud to present the successful results of their first 12 months.
Both the ASX200 Momentum Fund and the TAIL ASX200 Leveraged Fund have outperformed the set benchmarks of a net return of 13.6%.
The TAIM ASX200 Momentum Fund has provided a net return to their investors of 27.4% and the Leveraged Fund has a net return of 37.2%.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
